Status:
COMPLETED
Efficacy of Deep-coil Based Repetitive Transcranial Magnetic Stimulation in the Treatment of Parkinson's Disease With Freezing of Gait and Its Neural Regulation Mechanism Study of Resting-state Cerebral Blood Flow
Lead Sponsor:
Ningbo Medical Center Lihuili Hospital
Conditions:
Parkinson Disease
Freezing of Gait
Eligibility:
All Genders
45-70 years
Phase:
NA
Brief Summary
The protocol for repetitive transcranial magnetic stimulation (rTMS) in treating Parkinson's disease (PD) with freezing of gait (FOG) has not yet established an internationally unified standard, and t...
Detailed Description
Magstim rapid 2 transcranial magnetic stimulation instrument was used with double-cone coils, and the stimulation target was bilateral M1-LL. The total stimulation time of each target was 10 minutes, ...
Eligibility Criteria
Inclusion
- Meeting the clinical diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015.
- Aged between 45 and 70 years old, regardless of gender.
- Regularly taking anti - Parkinson's disease medications for a long time (≥3 years), accompanied by freezing of gait, and with poor efficacy of medications;
- A score of ≥24 on the Mini - Mental State Examination (MMSE).
- Signing the informed consent form and being willing to actively cooperate with the treatment.
Exclusion
- Freezing of gait caused by parkinsonism and parkinson plus syndromes.
- Having a history of central nervous system diseases such as cerebral infarction, cerebral hemorrhage, leukoencephalopathy, and migraine.
- Having been diagnosed with epilepsy or having had epileptic seizures.
- Having undergone craniocerebral surgery, having cerebral aneurysms or arteriovenous malformations, having metal implants in the skull, or having had a cardiac pacemaker implanted.
- Having a history of other mental illnesses or a family history of mental illnesses, such as schizophrenia, bipolar disorder, autism, mental retardation, depression, etc.
- Having received rTMS treatment.
- Severe PD (H\&Y grade ≥ 4).
- Severe organ dysfunction or severe physical diseases.
Key Trial Info
Start Date :
February 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06888778
Start Date
February 1 2023
End Date
December 1 2024
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ningbo Medical Center Li Huili Hospital, Ningbo, China
Ningbo, Zhejiang, China, 315100